196 related articles for article (PubMed ID: 32642284)
1. CMTM6 promotes cell proliferation and invasion in oral squamous cell carcinoma by interacting with NRP1.
Zheng Y; Wang C; Song A; Jiang F; Zhou J; Li G; Zhang W; Ye J; Ding X; Zhang W; Du Y; Zhang H; Wu H; Song X; Wu Y
Am J Cancer Res; 2020; 10(6):1691-1709. PubMed ID: 32642284
[TBL] [Abstract][Full Text] [Related]
2. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
3. Chemokine-like factor-like MARVEL transmembrane domain containing 6: Bioinformatics and experiments
Meng H; Li S; Li Q; Wang Y; Wang G; Qu Y
Front Mol Neurosci; 2022; 15():1026927. PubMed ID: 36698778
[TBL] [Abstract][Full Text] [Related]
4. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA OIP5-AS1 promotes the progression of oral squamous cell carcinoma via regulating miR-338-3p/NRP1 axis.
Li M; Ning J; Li Z; Fei Q; Zhao C; Ge Y; Wang L
Biomed Pharmacother; 2019 Oct; 118():109259. PubMed ID: 31369989
[TBL] [Abstract][Full Text] [Related]
6. CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis.
Mohapatra P; Mohanty S; Ansari SA; Shriwas O; Ghosh A; Rath R; Majumdar SKD; Swain RK; Raghav SK; Dash R
FASEB J; 2022 Oct; 36(10):e22566. PubMed ID: 36165231
[TBL] [Abstract][Full Text] [Related]
7. Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma.
Shahrabi-Farahani S; Gallottini M; Martins F; Li E; Mudge DR; Nakayama H; Hida K; Panigrahy D; D'Amore PA; Bielenberg DR
Am J Pathol; 2016 Apr; 186(4):1055-64. PubMed ID: 26877262
[TBL] [Abstract][Full Text] [Related]
8. Increased Expression of SHMT2 Is Associated With Poor Prognosis and Advanced Pathological Grade in Oral Squamous Cell Carcinoma.
Wu ZZ; Wang S; Yang QC; Wang XL; Yang LL; Liu B; Sun ZJ
Front Oncol; 2020; 10():588530. PubMed ID: 33163414
[TBL] [Abstract][Full Text] [Related]
9. CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.
Chen X; Shen H; Liu H; Tan L; Zhang N
Funct Integr Genomics; 2024 Jan; 24(1):10. PubMed ID: 38221563
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
[TBL] [Abstract][Full Text] [Related]
11. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
[TBL] [Abstract][Full Text] [Related]
12. Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity.
Wang H; Fan Y; Chen W; Lv Z; Wu S; Xuan Y; Wang C; Lu Y; Guo T; Shen D; Zhang F; Huang Q; Gao Y; Li H; Ma X; Wang B; Huang Y; Zhang X
Oncoimmunology; 2022; 11(1):2011673. PubMed ID: 35024247
[TBL] [Abstract][Full Text] [Related]
13. Expression and Clinical Significance of CMTM6 in Nonsmall Cell Lung Cancer.
Hou X; He S; Zhang D; Yang C; Shi Y; Zhang K
DNA Cell Biol; 2020 Oct; ():. PubMed ID: 33090010
[TBL] [Abstract][Full Text] [Related]
14. CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.
Huang X; Liu W; Liu C; Hu J; Wang B; Ren A; Huang X; Yuan Y; Liu J; Li M
Front Mol Biosci; 2022; 9():983410. PubMed ID: 36589225
[No Abstract] [Full Text] [Related]
15. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Zhang C; Zhao S; Wang X
Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study on neuropilin 1 (NRP1) immunoexpression in oral squamous cell carcinoma.
Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
Folia Histochem Cytobiol; 2018; 1(2):98-105. PubMed ID: 29873058
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer.
Yin B; Ding J; Hu H; Yang M; Huang B; Dong W; Li F; Han L
Front Mol Biosci; 2022; 9():769032. PubMed ID: 35174213
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.
Xu Y; Li Q; Lin H
Cell Signal; 2024 Mar; 115():111012. PubMed ID: 38113979
[TBL] [Abstract][Full Text] [Related]
19. CMTM6 knockdown prevents glioma progression by inactivating the mTOR pathway.
Wei L; Wei Q; Yang X; Zhou P
Ann Transl Med; 2022 Feb; 10(4):181. PubMed ID: 35280358
[TBL] [Abstract][Full Text] [Related]
20. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
Gao F; Chen J; Wang J; Li P; Wu S; Wang J; Ji Y
Biochem Biophys Rep; 2019 Dec; 20():100690. PubMed ID: 31646201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
